Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01624441 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Male Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma

Interventions

DRUG: Dinaciclib
DRUG: Epirubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)